TRCT
IMDX

Tower Research Capital (TRC)’s Insight Molecular Diagnostics IMDX Stock Holding History

Tower Research Capital (TRC)’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-250
Closed -$1.88K – 5427
2025
Q4 		$1.88K Sell
250
-374
-60% -$2.11K ﹤0.01% 4622
2025
Q3 		$2.07K Sell
624
-3,844
-86% -$10.8K ﹤0.01% 4685
2025
Q2 		$13.5K Buy
4,468
+3,304
+284% +$9.98K ﹤0.01% 3861
2025
Q1 		$3.56K Sell
1,164
-3,149
-73% -$8.51K ﹤0.01% 4390
2024
Q4 		$10.3K Buy
4,313
+2,867
+198% +$7.79K ﹤0.01% 3818
2024
Q3 		$4.12K Sell
1,446
-1,623
-53% -$5.04K ﹤0.01% 4665
2024
Q2 		$9.05K Buy
3,069
+1,189
+63% +$3.27K ﹤0.01% 4293
2024
Q1 		$5.51K Sell
1,880
-1,450
-44% -$4.48K ﹤0.01% 4534
2023
Q4 		$8.32K Buy
3,330
+774
+30% +$2.38K ﹤0.01% 4520
2023
Q3 		$7.97K Buy
2,556
+66
+3% +$246 ﹤0.01% 4413
2023
Q2 		$11.5K Buy
2,490
+578
+30% +$2.91K ﹤0.01% 3974
2023
Q1 		$14K Buy
1,912
+1,064
+125% +$7.9K ﹤0.01% 3901
2022
Q4 		$5K Buy
848
+173
+26% +$1.91K ﹤0.01% 4889
2022
Q3 		$10K Sell
675
-58
-8% -$1K ﹤0.01% 4555
2022
Q2 		$13K Sell
733
-40
-5% -$910 ﹤0.01% 4221
2022
Q1 		$23K Buy
773
+83
+12% +$2.65K ﹤0.01% 3398
2021
Q4 		$30K Buy
690
+327
+90% +$18.8K ﹤0.01% 3226
2021
Q3 		$26K Buy
363
+37
+11% +$3.4K ﹤0.01% 3484
2021
Q2 		$37K Buy
326
+180
+123% +$17.6K ﹤0.01% 3281
2021
Q1 		$15K Sell
146
-525
-78% -$49.9K ﹤0.01% 4113
2020
Q4 		$32K Sell
671
-2,004
-75% -$73.5K ﹤0.01% 3518
2020
Q3 		$74K Buy
2,675
+2,245
+522% +$64.4K ﹤0.01% 3362
2020
Q2 		$17K Buy
430
+107
+33% +$5.53K ﹤0.01% 3762
2020
Q1 		$16K Buy
323
+245
+314% +$12K ﹤0.01% 1824
2019
Q4 		$4K Buy
78
+35
+81% +$1.26K ﹤0.01% 2801
2019
Q3 		$2K Buy
43
+38
+760% +$1.49K ﹤0.01% 3714
2019
Q2 		$0 Sell
5
-143
-97% -$11.9K ﹤0.01% 4103
2019
Q1 		$12K Buy
148
+23
+18% +$1.48K ﹤0.01% 2581
2018
Q4 		$3K Buy
+125
New +$4.5K ﹤0.01% 3202
2018
Q2 		– Sell
-62
Closed -$3K – 3936
2018
Q1 		$3K Buy
62
+28
+82% +$1.85K ﹤0.01% 2867
2017
Q4 		$3K Buy
+34
New +$3.83K ﹤0.01% 3097
2017
Q3 		– Sell
-35
Closed -$4K – 4047
2017
Q2 		$4K Sell
35
-1
-3% -$114 ﹤0.01% 2108
2017
Q1 		$4K Buy
+36
New +$4.16K ﹤0.01% 2332
2016
Q4 		– Sell
-37
Closed -$4K – 4231
2016
Q3 		$4K Sell
37
-69
-65% -$5.57K ﹤0.01% 2695
2016
Q2 		$8K Buy
106
+56
+112% +$5.23K ﹤0.01% 3033
2016
Q1 		$4K Buy
+50
New +$4.43K ﹤0.01% 2913

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Tower Research Capital (TRC)'s IMDX Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Insight Molecular Diagnostics (IMDX) in Q1 2026, closing a stake of 250 shares — an estimated $1.88K sold.

Tower Research Capital (TRC) first reported a position in IMDX in Q1 2016 and held it in 36 quarters. The position peaked at $74K in Q3 2020. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Insight Molecular Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 250 Insight Molecular Diagnostics shares in Q1 2026, an estimated $1.88K.
  • Tower Research Capital (TRC) first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 36 quarters.
  • Tower Research Capital (TRC)'s Insight Molecular Diagnostics position peaked at $74K in Q3 2020.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.